Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?

Boston Scientific (BSX) currently holds an average brokerage recommendation (ABR) of 1.14, approximating a Strong Buy, based on ratings from 29 brokerage firms; however, the article suggests that investors should not rely solely on ABRs due to inherent biases in brokerage firm recommendations. While the Zacks Consensus Estimate for the current year has increased to $2.91, the article emphasizes using the ABR in conjunction with the Zacks Rank, a proprietary stock rating tool driven by earnings estimate revisions, for more informed investment decisions.

Analysis

Boston Scientific (BSX) exhibits strong positive sentiment among Wall Street analysts, evidenced by an Average Brokerage Recommendation (ABR) of 1.14, which approximates a Strong Buy. This ABR is derived from 29 brokerage firms, with 26 rating it a Strong Buy and two a Buy, translating to 89.7% and 6.9% of all recommendations, respectively. However, the article cautions against relying solely on ABRs due to potential biases, as brokerage firms tend to issue a disproportionately high number of 'Strong Buy' ratings. Instead, it advocates for using ABRs to validate other indicators, such as the Zacks Rank. For BSX, the Zacks Consensus Estimate for current year EPS stands at $2.91, reflecting a 0% change over the past month, yet analysts show strong agreement in revising EPS estimates higher, which could signal near-term stock appreciation. This, along with other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Boston Scientific, suggesting a favorable outlook driven by earnings estimate revisions, which are considered a strong predictor of near-term stock price movements.

Key Decisions for Investors

• Investors should consider the strong positive analyst consensus on Boston Scientific (ABR 1.14, Zacks Rank #2 Buy) as a bullish signal, but validate this with their own fundamental research, particularly focusing on earnings estimate trends.
• Be mindful of the inherent positive bias in sell-side analyst recommendations; use the ABR primarily as a supplementary tool to other quantitative measures like the Zacks Rank, which is driven by earnings estimate revisions.
• Monitor ongoing revisions to Boston Scientific's earnings estimates, as the strong agreement among analysts revising EPS higher is highlighted as a key driver for potential near-term stock performance.